<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://www.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Fri, 12 Jun 2026 16:22:00 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://www.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>Form  S-8        Atara Biotherapeutics,               </title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Atara+Biotherapeutics%2C+++++++++++++++/26641177.html</link>
   <description>si-local-file:///var/storage/secattach/20260612/26641177.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Atara+Biotherapeutics%2C+++++++++++++++/26641177.html</guid>
   <pubDate>Fri, 12 Jun 2026 16:22:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ATRA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14891995</category>
   	  </item>
  <item>
   <title>Form  S-8        Atara Biotherapeutics,               </title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Atara+Biotherapeutics%2C+++++++++++++++/26641177.html</link>
   <description>si-local-file:///var/storage/secattach/20260612/26641177.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Atara+Biotherapeutics%2C+++++++++++++++/26641177.html</guid>
   <pubDate>Fri, 12 Jun 2026 16:22:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ATRA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14891995</category>
   	  </item>
  <item>
   <title>Form  8-K        Atara Biotherapeutics,    For: Jun 09</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Atara+Biotherapeutics%2C++++For%3A+Jun+09/26640714.html</link>
   <description>si-local-file:///var/storage/secattach/20260612/26640714.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Atara+Biotherapeutics%2C++++For%3A+Jun+09/26640714.html</guid>
   <pubDate>Fri, 12 Jun 2026 16:07:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ATRA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14891995</category>
   	  </item>
  <item>
   <title>Form  8-K        Atara Biotherapeutics,    For: Jun 09</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Atara+Biotherapeutics%2C++++For%3A+Jun+09/26640714.html</link>
   <description>si-local-file:///var/storage/secattach/20260612/26640714.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Atara+Biotherapeutics%2C++++For%3A+Jun+09/26640714.html</guid>
   <pubDate>Fri, 12 Jun 2026 16:07:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ATRA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14891995</category>
   	  </item>
  <item>
   <title>Atara Biotherapeutics makes board changes with departure and new appointment</title>
   <link>http://www.streetinsider.com/Board+Changes/Atara+Biotherapeutics+makes+board+changes+with+departure+and+new+appointment/26640498.html</link>
   <description>

&lt;p&gt;Atara Biotherapeutics, Inc. (NASDAQ: ATRA) announced board of directors changes, with Carol Gallagher departing after 13 years of service and Brian Cherry joining as a new member.&lt;/p&gt;

&lt;p&gt;Gallagher, who holds a Pharm.D., served in multiple roles during her tenure on the board. Cokey Nguyen, President and Chief Executive Officer, acknowledged her dedication to the company and shareholders over the past 13 years.&lt;/p&gt;

&lt;p&gt;Cherry brings more than 25 years of investment experience across healthcare, industrials, business services, financial services and consumer products sectors. He previously led buyout and growth equity investments totaling over $25 billion in enterprise value as a Managing Partner at</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Board+Changes/Atara+Biotherapeutics+makes+board+changes+with+departure+and+new+appointment/26640498.html</guid>
   <pubDate>Fri, 12 Jun 2026 16:00:18 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.03607790</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.09181861</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATRA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304018</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14891995</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20147506</category>
   	  </item>
  <item>
   <title>Atara Biotherapeutics makes board changes with departure and new appointment</title>
   <link>http://www.streetinsider.com/Board+Changes/Atara+Biotherapeutics+makes+board+changes+with+departure+and+new+appointment/26640498.html</link>
   <description>

&lt;p&gt;Atara Biotherapeutics, Inc. (NASDAQ: ATRA) announced board of directors changes, with Carol Gallagher departing after 13 years of service and Brian Cherry joining as a new member.&lt;/p&gt;

&lt;p&gt;Gallagher, who holds a Pharm.D., served in multiple roles during her tenure on the board. Cokey Nguyen, President and Chief Executive Officer, acknowledged her dedication to the company and shareholders over the past 13 years.&lt;/p&gt;

&lt;p&gt;Cherry brings more than 25 years of investment experience across healthcare, industrials, business services, financial services and consumer products sectors. He previously led buyout and growth equity investments totaling over $25 billion in enterprise value as a Managing Partner at</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Board+Changes/Atara+Biotherapeutics+makes+board+changes+with+departure+and+new+appointment/26640498.html</guid>
   <pubDate>Fri, 12 Jun 2026 16:00:18 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.03607790</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.09181861</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATRA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304018</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14891995</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20147506</category>
   	  </item>
  <item>
   <title>Atara Biotherapeutics makes board changes with departure and new appointment</title>
   <link>http://www.streetinsider.com/Board+Changes/Atara+Biotherapeutics+makes+board+changes+with+departure+and+new+appointment/26640498.html</link>
   <description>

&lt;p&gt;Atara Biotherapeutics, Inc. (NASDAQ: ATRA) announced board of directors changes, with Carol Gallagher departing after 13 years of service and Brian Cherry joining as a new member.&lt;/p&gt;

&lt;p&gt;Gallagher, who holds a Pharm.D., served in multiple roles during her tenure on the board. Cokey Nguyen, President and Chief Executive Officer, acknowledged her dedication to the company and shareholders over the past 13 years.&lt;/p&gt;

&lt;p&gt;Cherry brings more than 25 years of investment experience across healthcare, industrials, business services, financial services and consumer products sectors. He previously led buyout and growth equity investments totaling over $25 billion in enterprise value as a Managing Partner at</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Board+Changes/Atara+Biotherapeutics+makes+board+changes+with+departure+and+new+appointment/26640498.html</guid>
   <pubDate>Fri, 12 Jun 2026 16:00:18 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.03607790</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.09181861</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATRA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304018</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14891995</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20147506</category>
   	  </item>
  <item>
   <title>Atara Biotherapeutics makes board changes with departure and new appointment</title>
   <link>http://www.streetinsider.com/Board+Changes/Atara+Biotherapeutics+makes+board+changes+with+departure+and+new+appointment/26640498.html</link>
   <description>

&lt;p&gt;Atara Biotherapeutics, Inc. (NASDAQ: ATRA) announced board of directors changes, with Carol Gallagher departing after 13 years of service and Brian Cherry joining as a new member.&lt;/p&gt;

&lt;p&gt;Gallagher, who holds a Pharm.D., served in multiple roles during her tenure on the board. Cokey Nguyen, President and Chief Executive Officer, acknowledged her dedication to the company and shareholders over the past 13 years.&lt;/p&gt;

&lt;p&gt;Cherry brings more than 25 years of investment experience across healthcare, industrials, business services, financial services and consumer products sectors. He previously led buyout and growth equity investments totaling over $25 billion in enterprise value as a Managing Partner at</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Board+Changes/Atara+Biotherapeutics+makes+board+changes+with+departure+and+new+appointment/26640498.html</guid>
   <pubDate>Fri, 12 Jun 2026 16:00:18 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.03607790</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.09181861</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATRA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304018</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14891995</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20147506</category>
   	  </item>
  <item>
   <title>Atara Biotherapeutics makes board changes with departure and new appointment</title>
   <link>http://www.streetinsider.com/Board+Changes/Atara+Biotherapeutics+makes+board+changes+with+departure+and+new+appointment/26640498.html</link>
   <description>

&lt;p&gt;Atara Biotherapeutics, Inc. (NASDAQ: ATRA) announced board of directors changes, with Carol Gallagher departing after 13 years of service and Brian Cherry joining as a new member.&lt;/p&gt;

&lt;p&gt;Gallagher, who holds a Pharm.D., served in multiple roles during her tenure on the board. Cokey Nguyen, President and Chief Executive Officer, acknowledged her dedication to the company and shareholders over the past 13 years.&lt;/p&gt;

&lt;p&gt;Cherry brings more than 25 years of investment experience across healthcare, industrials, business services, financial services and consumer products sectors. He previously led buyout and growth equity investments totaling over $25 billion in enterprise value as a Managing Partner at</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Board+Changes/Atara+Biotherapeutics+makes+board+changes+with+departure+and+new+appointment/26640498.html</guid>
   <pubDate>Fri, 12 Jun 2026 16:00:18 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.03607790</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.09181861</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATRA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304018</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14891995</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20147506</category>
   	  </item>
  <item>
   <title>Atara Biotherapeutics makes board changes with departure and new appointment</title>
   <link>http://www.streetinsider.com/Board+Changes/Atara+Biotherapeutics+makes+board+changes+with+departure+and+new+appointment/26640498.html</link>
   <description>

&lt;p&gt;Atara Biotherapeutics, Inc. (NASDAQ: ATRA) announced board of directors changes, with Carol Gallagher departing after 13 years of service and Brian Cherry joining as a new member.&lt;/p&gt;

&lt;p&gt;Gallagher, who holds a Pharm.D., served in multiple roles during her tenure on the board. Cokey Nguyen, President and Chief Executive Officer, acknowledged her dedication to the company and shareholders over the past 13 years.&lt;/p&gt;

&lt;p&gt;Cherry brings more than 25 years of investment experience across healthcare, industrials, business services, financial services and consumer products sectors. He previously led buyout and growth equity investments totaling over $25 billion in enterprise value as a Managing Partner at</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Board+Changes/Atara+Biotherapeutics+makes+board+changes+with+departure+and+new+appointment/26640498.html</guid>
   <pubDate>Fri, 12 Jun 2026 16:00:18 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.03607790</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.09181861</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATRA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304018</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14891995</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20147506</category>
   	  </item>
  <item>
   <title>Atara Biotherapeutics Announces Changes to Its Board of Directors</title>
   <link>http://www.streetinsider.com/Press+Releases/Atara+Biotherapeutics+Announces+Changes+to+Its+Board+of+Directors/26640494.html</link>
   <description>
&lt;p&gt;    THOUSAND OAKS, Calif.--(BUSINESS WIRE)--
&lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Fwww.atarabio.com%2F&amp;amp;esheet=54553065&amp;amp;newsitemid=20260612613594&amp;amp;lan=en-US&amp;amp;anchor=Atara+Biotherapeutics%2C+Inc.&amp;amp;index=1&amp;amp;md5=ac47280ffb8e94d8eed277fda2ce252d&quot; shape=&quot;rect&quot;&gt;Atara Biotherapeutics, Inc.&lt;/a&gt; (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the departure of Carol Gallagher, Pharm D from its Board of Directors.

&lt;/p&gt;&lt;p&gt;
“On behalf of Atara and its Board of Directors, I want to express my gratitude to Carol for her dedication to our company and its shareholders over the past thirteen years,” said Cokey Nguyen, President and Chief Executive Officer of Atara. “Carol has been a pillar</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Atara+Biotherapeutics+Announces+Changes+to+Its+Board+of+Directors/26640494.html</guid>
   <pubDate>Fri, 12 Jun 2026 16:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.03607790</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.09181861</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATRA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304018</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14891995</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20147506</category>
   	  </item>
  <item>
   <title>Atara Biotherapeutics Announces Changes to Its Board of Directors</title>
   <link>http://www.streetinsider.com/Press+Releases/Atara+Biotherapeutics+Announces+Changes+to+Its+Board+of+Directors/26640494.html</link>
   <description>
&lt;p&gt;    THOUSAND OAKS, Calif.--(BUSINESS WIRE)--
&lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Fwww.atarabio.com%2F&amp;amp;esheet=54553065&amp;amp;newsitemid=20260612613594&amp;amp;lan=en-US&amp;amp;anchor=Atara+Biotherapeutics%2C+Inc.&amp;amp;index=1&amp;amp;md5=ac47280ffb8e94d8eed277fda2ce252d&quot; shape=&quot;rect&quot;&gt;Atara Biotherapeutics, Inc.&lt;/a&gt; (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the departure of Carol Gallagher, Pharm D from its Board of Directors.

&lt;/p&gt;&lt;p&gt;
“On behalf of Atara and its Board of Directors, I want to express my gratitude to Carol for her dedication to our company and its shareholders over the past thirteen years,” said Cokey Nguyen, President and Chief Executive Officer of Atara. “Carol has been a pillar</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Atara+Biotherapeutics+Announces+Changes+to+Its+Board+of+Directors/26640494.html</guid>
   <pubDate>Fri, 12 Jun 2026 16:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.03607790</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.09181861</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATRA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304018</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14891995</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20147506</category>
   	  </item>
  <item>
   <title>Atara Biotherapeutics Announces Changes to Its Board of Directors</title>
   <link>http://www.streetinsider.com/Press+Releases/Atara+Biotherapeutics+Announces+Changes+to+Its+Board+of+Directors/26640494.html</link>
   <description>
&lt;p&gt;    THOUSAND OAKS, Calif.--(BUSINESS WIRE)--
&lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Fwww.atarabio.com%2F&amp;amp;esheet=54553065&amp;amp;newsitemid=20260612613594&amp;amp;lan=en-US&amp;amp;anchor=Atara+Biotherapeutics%2C+Inc.&amp;amp;index=1&amp;amp;md5=ac47280ffb8e94d8eed277fda2ce252d&quot; shape=&quot;rect&quot;&gt;Atara Biotherapeutics, Inc.&lt;/a&gt; (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the departure of Carol Gallagher, Pharm D from its Board of Directors.

&lt;/p&gt;&lt;p&gt;
“On behalf of Atara and its Board of Directors, I want to express my gratitude to Carol for her dedication to our company and its shareholders over the past thirteen years,” said Cokey Nguyen, President and Chief Executive Officer of Atara. “Carol has been a pillar</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Atara+Biotherapeutics+Announces+Changes+to+Its+Board+of+Directors/26640494.html</guid>
   <pubDate>Fri, 12 Jun 2026 16:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.03607790</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.09181861</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATRA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304018</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14891995</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20147506</category>
   	  </item>
  <item>
   <title>Atara Biotherapeutics Announces Changes to Its Board of Directors</title>
   <link>http://www.streetinsider.com/Press+Releases/Atara+Biotherapeutics+Announces+Changes+to+Its+Board+of+Directors/26640494.html</link>
   <description>
&lt;p&gt;    THOUSAND OAKS, Calif.--(BUSINESS WIRE)--
&lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Fwww.atarabio.com%2F&amp;amp;esheet=54553065&amp;amp;newsitemid=20260612613594&amp;amp;lan=en-US&amp;amp;anchor=Atara+Biotherapeutics%2C+Inc.&amp;amp;index=1&amp;amp;md5=ac47280ffb8e94d8eed277fda2ce252d&quot; shape=&quot;rect&quot;&gt;Atara Biotherapeutics, Inc.&lt;/a&gt; (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the departure of Carol Gallagher, Pharm D from its Board of Directors.

&lt;/p&gt;&lt;p&gt;
“On behalf of Atara and its Board of Directors, I want to express my gratitude to Carol for her dedication to our company and its shareholders over the past thirteen years,” said Cokey Nguyen, President and Chief Executive Officer of Atara. “Carol has been a pillar</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Atara+Biotherapeutics+Announces+Changes+to+Its+Board+of+Directors/26640494.html</guid>
   <pubDate>Fri, 12 Jun 2026 16:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.03607790</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.09181861</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATRA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304018</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14891995</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20147506</category>
   	  </item>
  <item>
   <title>Atara Biotherapeutics Announces Changes to Its Board of Directors</title>
   <link>http://www.streetinsider.com/Press+Releases/Atara+Biotherapeutics+Announces+Changes+to+Its+Board+of+Directors/26640494.html</link>
   <description>
&lt;p&gt;    THOUSAND OAKS, Calif.--(BUSINESS WIRE)--
&lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Fwww.atarabio.com%2F&amp;amp;esheet=54553065&amp;amp;newsitemid=20260612613594&amp;amp;lan=en-US&amp;amp;anchor=Atara+Biotherapeutics%2C+Inc.&amp;amp;index=1&amp;amp;md5=ac47280ffb8e94d8eed277fda2ce252d&quot; shape=&quot;rect&quot;&gt;Atara Biotherapeutics, Inc.&lt;/a&gt; (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the departure of Carol Gallagher, Pharm D from its Board of Directors.

&lt;/p&gt;&lt;p&gt;
“On behalf of Atara and its Board of Directors, I want to express my gratitude to Carol for her dedication to our company and its shareholders over the past thirteen years,” said Cokey Nguyen, President and Chief Executive Officer of Atara. “Carol has been a pillar</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Atara+Biotherapeutics+Announces+Changes+to+Its+Board+of+Directors/26640494.html</guid>
   <pubDate>Fri, 12 Jun 2026 16:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.03607790</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.09181861</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATRA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304018</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14891995</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20147506</category>
   	  </item>
  <item>
   <title>Atara Biotherapeutics Announces Changes to Its Board of Directors</title>
   <link>http://www.streetinsider.com/Press+Releases/Atara+Biotherapeutics+Announces+Changes+to+Its+Board+of+Directors/26640494.html</link>
   <description>
&lt;p&gt;    THOUSAND OAKS, Calif.--(BUSINESS WIRE)--
&lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Fwww.atarabio.com%2F&amp;amp;esheet=54553065&amp;amp;newsitemid=20260612613594&amp;amp;lan=en-US&amp;amp;anchor=Atara+Biotherapeutics%2C+Inc.&amp;amp;index=1&amp;amp;md5=ac47280ffb8e94d8eed277fda2ce252d&quot; shape=&quot;rect&quot;&gt;Atara Biotherapeutics, Inc.&lt;/a&gt; (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the departure of Carol Gallagher, Pharm D from its Board of Directors.

&lt;/p&gt;&lt;p&gt;
“On behalf of Atara and its Board of Directors, I want to express my gratitude to Carol for her dedication to our company and its shareholders over the past thirteen years,” said Cokey Nguyen, President and Chief Executive Officer of Atara. “Carol has been a pillar</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Atara+Biotherapeutics+Announces+Changes+to+Its+Board+of+Directors/26640494.html</guid>
   <pubDate>Fri, 12 Jun 2026 16:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.03607790</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.09181861</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATRA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304018</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14891995</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20147506</category>
   	  </item>
  <item>
   <title>Atara Biotherapeutics Announces Changes to Its Board of Directors</title>
   <link>http://www.streetinsider.com/Business+Wire/Atara+Biotherapeutics+Announces+Changes+to+Its+Board+of+Directors/26640494.html</link>
   <description>
&lt;p&gt;    THOUSAND OAKS, Calif.--(BUSINESS WIRE)--
&lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Fwww.atarabio.com%2F&amp;amp;esheet=54553065&amp;amp;newsitemid=20260612613594&amp;amp;lan=en-US&amp;amp;anchor=Atara+Biotherapeutics%2C+Inc.&amp;amp;index=1&amp;amp;md5=ac47280ffb8e94d8eed277fda2ce252d&quot; shape=&quot;rect&quot;&gt;Atara Biotherapeutics, Inc.&lt;/a&gt; (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the departure of Carol Gallagher, Pharm D from its Board of Directors.

&lt;/p&gt;&lt;p&gt;
“On behalf of Atara and its Board of Directors, I want to express my gratitude to Carol for her dedication to our company and its shareholders over the past thirteen years,” said Cokey Nguyen, President and Chief Executive Officer of Atara. “Carol has been a pillar</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Atara+Biotherapeutics+Announces+Changes+to+Its+Board+of+Directors/26640494.html</guid>
   <pubDate>Fri, 12 Jun 2026 16:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.03607790</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.09181861</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATRA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304018</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14891995</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20147506</category>
   	  </item>
  <item>
   <title>Atara Biotherapeutics Announces Changes to Its Board of Directors</title>
   <link>http://www.streetinsider.com/Business+Wire/Atara+Biotherapeutics+Announces+Changes+to+Its+Board+of+Directors/26640494.html</link>
   <description>
&lt;p&gt;    THOUSAND OAKS, Calif.--(BUSINESS WIRE)--
&lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Fwww.atarabio.com%2F&amp;amp;esheet=54553065&amp;amp;newsitemid=20260612613594&amp;amp;lan=en-US&amp;amp;anchor=Atara+Biotherapeutics%2C+Inc.&amp;amp;index=1&amp;amp;md5=ac47280ffb8e94d8eed277fda2ce252d&quot; shape=&quot;rect&quot;&gt;Atara Biotherapeutics, Inc.&lt;/a&gt; (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the departure of Carol Gallagher, Pharm D from its Board of Directors.

&lt;/p&gt;&lt;p&gt;
“On behalf of Atara and its Board of Directors, I want to express my gratitude to Carol for her dedication to our company and its shareholders over the past thirteen years,” said Cokey Nguyen, President and Chief Executive Officer of Atara. “Carol has been a pillar</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Atara+Biotherapeutics+Announces+Changes+to+Its+Board+of+Directors/26640494.html</guid>
   <pubDate>Fri, 12 Jun 2026 16:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.03607790</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.09181861</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATRA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304018</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14891995</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20147506</category>
   	  </item>
  <item>
   <title>Atara Biotherapeutics Announces Changes to Its Board of Directors</title>
   <link>http://www.streetinsider.com/Business+Wire/Atara+Biotherapeutics+Announces+Changes+to+Its+Board+of+Directors/26640494.html</link>
   <description>
&lt;p&gt;    THOUSAND OAKS, Calif.--(BUSINESS WIRE)--
&lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Fwww.atarabio.com%2F&amp;amp;esheet=54553065&amp;amp;newsitemid=20260612613594&amp;amp;lan=en-US&amp;amp;anchor=Atara+Biotherapeutics%2C+Inc.&amp;amp;index=1&amp;amp;md5=ac47280ffb8e94d8eed277fda2ce252d&quot; shape=&quot;rect&quot;&gt;Atara Biotherapeutics, Inc.&lt;/a&gt; (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the departure of Carol Gallagher, Pharm D from its Board of Directors.

&lt;/p&gt;&lt;p&gt;
“On behalf of Atara and its Board of Directors, I want to express my gratitude to Carol for her dedication to our company and its shareholders over the past thirteen years,” said Cokey Nguyen, President and Chief Executive Officer of Atara. “Carol has been a pillar</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Atara+Biotherapeutics+Announces+Changes+to+Its+Board+of+Directors/26640494.html</guid>
   <pubDate>Fri, 12 Jun 2026 16:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.03607790</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.09181861</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATRA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304018</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14891995</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20147506</category>
   	  </item>
  <item>
   <title>Atara Biotherapeutics Announces Changes to Its Board of Directors</title>
   <link>http://www.streetinsider.com/Business+Wire/Atara+Biotherapeutics+Announces+Changes+to+Its+Board+of+Directors/26640494.html</link>
   <description>
&lt;p&gt;    THOUSAND OAKS, Calif.--(BUSINESS WIRE)--
&lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Fwww.atarabio.com%2F&amp;amp;esheet=54553065&amp;amp;newsitemid=20260612613594&amp;amp;lan=en-US&amp;amp;anchor=Atara+Biotherapeutics%2C+Inc.&amp;amp;index=1&amp;amp;md5=ac47280ffb8e94d8eed277fda2ce252d&quot; shape=&quot;rect&quot;&gt;Atara Biotherapeutics, Inc.&lt;/a&gt; (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the departure of Carol Gallagher, Pharm D from its Board of Directors.

&lt;/p&gt;&lt;p&gt;
“On behalf of Atara and its Board of Directors, I want to express my gratitude to Carol for her dedication to our company and its shareholders over the past thirteen years,” said Cokey Nguyen, President and Chief Executive Officer of Atara. “Carol has been a pillar</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Atara+Biotherapeutics+Announces+Changes+to+Its+Board+of+Directors/26640494.html</guid>
   <pubDate>Fri, 12 Jun 2026 16:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.03607790</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.09181861</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATRA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304018</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14891995</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20147506</category>
   	  </item>
  <item>
   <title>Atara Biotherapeutics Announces Changes to Its Board of Directors</title>
   <link>http://www.streetinsider.com/Business+Wire/Atara+Biotherapeutics+Announces+Changes+to+Its+Board+of+Directors/26640494.html</link>
   <description>
&lt;p&gt;    THOUSAND OAKS, Calif.--(BUSINESS WIRE)--
&lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Fwww.atarabio.com%2F&amp;amp;esheet=54553065&amp;amp;newsitemid=20260612613594&amp;amp;lan=en-US&amp;amp;anchor=Atara+Biotherapeutics%2C+Inc.&amp;amp;index=1&amp;amp;md5=ac47280ffb8e94d8eed277fda2ce252d&quot; shape=&quot;rect&quot;&gt;Atara Biotherapeutics, Inc.&lt;/a&gt; (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the departure of Carol Gallagher, Pharm D from its Board of Directors.

&lt;/p&gt;&lt;p&gt;
“On behalf of Atara and its Board of Directors, I want to express my gratitude to Carol for her dedication to our company and its shareholders over the past thirteen years,” said Cokey Nguyen, President and Chief Executive Officer of Atara. “Carol has been a pillar</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Atara+Biotherapeutics+Announces+Changes+to+Its+Board+of+Directors/26640494.html</guid>
   <pubDate>Fri, 12 Jun 2026 16:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.03607790</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.09181861</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATRA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304018</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14891995</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20147506</category>
   	  </item>
  <item>
   <title>Atara Biotherapeutics Announces Changes to Its Board of Directors</title>
   <link>http://www.streetinsider.com/Business+Wire/Atara+Biotherapeutics+Announces+Changes+to+Its+Board+of+Directors/26640494.html</link>
   <description>
&lt;p&gt;    THOUSAND OAKS, Calif.--(BUSINESS WIRE)--
&lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=https%3A%2F%2Fwww.atarabio.com%2F&amp;amp;esheet=54553065&amp;amp;newsitemid=20260612613594&amp;amp;lan=en-US&amp;amp;anchor=Atara+Biotherapeutics%2C+Inc.&amp;amp;index=1&amp;amp;md5=ac47280ffb8e94d8eed277fda2ce252d&quot; shape=&quot;rect&quot;&gt;Atara Biotherapeutics, Inc.&lt;/a&gt; (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the departure of Carol Gallagher, Pharm D from its Board of Directors.

&lt;/p&gt;&lt;p&gt;
“On behalf of Atara and its Board of Directors, I want to express my gratitude to Carol for her dedication to our company and its shareholders over the past thirteen years,” said Cokey Nguyen, President and Chief Executive Officer of Atara. “Carol has been a pillar</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Atara+Biotherapeutics+Announces+Changes+to+Its+Board+of+Directors/26640494.html</guid>
   <pubDate>Fri, 12 Jun 2026 16:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.03607790</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.09181861</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATRA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304018</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14891995</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20147506</category>
   	  </item>
  <item>
   <title>Form  4          Atara Biotherapeutics,    For: Jun 09  Filed by: HEIDEN WILLIAM K</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Atara+Biotherapeutics%2C++++For%3A+Jun+09++Filed+by%3A+HEIDEN+WILLIAM+K/26636344.html</link>
   <description>si-local-file:///var/storage/secattach/20260611/26636344.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Atara+Biotherapeutics%2C++++For%3A+Jun+09++Filed+by%3A+HEIDEN+WILLIAM+K/26636344.html</guid>
   <pubDate>Thu, 11 Jun 2026 16:38:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ATRA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14891995</category>
   	  </item>
  <item>
   <title>Form  4          Atara Biotherapeutics,    For: Jun 09  Filed by: HEIDEN WILLIAM K</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Atara+Biotherapeutics%2C++++For%3A+Jun+09++Filed+by%3A+HEIDEN+WILLIAM+K/26636344.html</link>
   <description>si-local-file:///var/storage/secattach/20260611/26636344.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Atara+Biotherapeutics%2C++++For%3A+Jun+09++Filed+by%3A+HEIDEN+WILLIAM+K/26636344.html</guid>
   <pubDate>Thu, 11 Jun 2026 16:38:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ATRA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14891995</category>
   	  </item>
  <item>
   <title>Form  4          Atara Biotherapeutics,    For: Jun 09  Filed by: Fust Matthew K</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Atara+Biotherapeutics%2C++++For%3A+Jun+09++Filed+by%3A+Fust+Matthew+K/26636322.html</link>
   <description>si-local-file:///var/storage/secattach/20260611/26636322.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Atara+Biotherapeutics%2C++++For%3A+Jun+09++Filed+by%3A+Fust+Matthew+K/26636322.html</guid>
   <pubDate>Thu, 11 Jun 2026 16:37:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ATRA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.14891995</category>
   	  </item>
 </channel>
</rss>
